{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:34:02Z","timestamp":1740720842589,"version":"3.38.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Multiple Sclerosis (MS) is the first cause of non-traumatic neurological disability in young adults. Primary and secondary progressive MS are still lacking effective treatments. A new nutraceutical product made of lyophilised leaves of bioengineered kiwi plants (<jats:italic>Actinidia deliciosa<\/jats:italic>) overexpressing osmotin has recently been developed. Osmotin is a protein associated with stress adaptation in plant cells and it shares anti-inflammatory and neuroprotective properties with mammalian adiponectin. The aim of this study is to explore the safety and the efficacy of osmotin in progressive MS (PMS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This is a prospective, multicenter, single-arm interventional, baseline vs treatment study that will be carried out by two Italian MS centers, where a total of fifty PMS patients will be recruited. Every patient will take a daily dosage of 5 grams of an osmotin-based nutraceutical, named Forza\u2122 (9<jats:sup>th<\/jats:sup> Dimension Biotech, Inc.), for 6 months. Two pre-treatment assessments, at -6 months (-6M) and at baseline visit (M0), and two post-treatment assessments, at month 1 (M1), and at month 6 (M6) will be carried out. Forza<jats:sup>TM<\/jats:sup> safety and activity, assessed by serum Neurofilaments Light (NfL) Chain quantification, are the primary outcomes of the study. Additional assessments will consist of clinical and neuropsychological evaluations, patient reported outcomes (PROs), brain magnetic resonance imaging (MRI), motor evoked potentials (MEPs) and optical coherence tomography (OCT).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Discussion<\/jats:title>\n<jats:p>Disease modifying treatments in MS usually target inflammatory pathways with excellent results on reducing relapse associated disability but fail in preventing progression independent from relapse activity. This is a proof-of-concept study aimed at exploring the safety and the activity of an osmotin-based nutraceutical as an adjuvant treatment in PMS patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The trial was registered on July 10<jats:sup>th<\/jats:sup> 2023 at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/\" xlink:type=\"simple\">www.clinicaltrials.gov<\/jats:ext-link> having identifier <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05937802\" xlink:type=\"simple\">NCT05937802<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0311214","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:26:50Z","timestamp":1740680810000},"page":"e0311214","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study protocol: Exploratory trial of Forza\u2122, an osmotin-based nutraceutical as adjuvant for the treatment of progressive multiple sclerosis"],"prefix":"10.1371","volume":"20","author":[{"given":"Viola","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenda","family":"Aluan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Bason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Vigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Leveraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Cabona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9073-1082","authenticated-orcid":true,"given":"Mauro","family":"Costagli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo Daniele","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-3572","authenticated-orcid":true,"given":"Giampaolo","family":"Brichetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Mancardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Alberto","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"5","key":"pone.0311214.ref001","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"N Koch-Henriksen","year":"2010","journal-title":"The Lancet Neurology"},{"issue":"9","key":"pone.0311214.ref002","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"FD Lublin","year":"2022","journal-title":"Brain"},{"issue":"7","key":"pone.0311214.ref003","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/cdd.2009.179","article-title":"The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis","volume":"17","author":"D Centonze","year":"2010","journal-title":"Cell Death and Differentiation [Internet]"},{"key":"pone.0311214.ref004","article-title":"Facing the urgency of therapies for progressive MS\u2014a Progressive MS Alliance proposal","author":"F Dangond","year":"2021","journal-title":"Nature Reviews Neurology"},{"issue":"5","key":"pone.0311214.ref005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity\u2013free relapsing multiple sclerosis","volume":"85","author":"BAC Cree","year":"2019","journal-title":"Annals of Neurology"},{"issue":"9","key":"pone.0311214.ref006","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"L Kappos","year":"2020","journal-title":"JAMA Neurology"},{"issue":"3","key":"pone.0311214.ref007","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamaneurol.2018.4932","article-title":"Potential Benefits of Early Aggressive Treatment in Multiple Sclerosis","volume":"76","author":"AJ Green","year":"2019","journal-title":"JAMA Neurology"},{"key":"pone.0311214.ref008","doi-asserted-by":"crossref","first-page":"101486","DOI":"10.1016\/j.msard.2019.101486","article-title":"The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review","volume":"37","author":"W Marx","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"pone.0311214.ref009","first-page":"529","article-title":"Characterization of Osmotin","volume":"85","author":"NK Singh","year":"1987"},{"key":"pone.0311214.ref010","author":"E Rugini","journal-title":"KIWIFRUIT TRANSGENICS FOR OSMOTIN GENE AND INOCULATION TESTS WITH BOTRYTIS CINEREA AND CADOPHORA LUTEO-OLIVACEA | International Society for Horticultural Science [Internet]"},{"issue":"10","key":"pone.0311214.ref011","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/nu10101399","article-title":"A Water-Soluble Extract from Actinidia arguta Ameliorates Psoriasis-Like Skin Inflammation in Mice by Inhibition of Neutrophil Infiltration","volume":"10","author":"H Kim","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"pone.0311214.ref012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11248-013-9740-5","article-title":"Osmotin-expressing transgenic tea plants have improved stress tolerance and are of higher quality","volume":"23","author":"A Bhattacharya","year":"2013","journal-title":"Transgenic Research"},{"issue":"2","key":"pone.0311214.ref013","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2004.11.050","article-title":"Osmotin Is a Homolog of Mammalian Adiponectin and Controls Apoptosis in Yeast through a Homolog of Mammalian Adiponectin Receptor","volume":"17","author":"ML Narasimhan","year":"2005","journal-title":"Molecular Cell"},{"issue":"10","key":"pone.0311214.ref014","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.biochi.2012.05.018","article-title":"Immunological functions of leptin and adiponectin","volume":"94","author":"F Carbone","year":"2012","journal-title":"Biochimie [Internet]"},{"key":"pone.0311214.ref015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.metabol.2018.01.010","article-title":"Novel phytopeptide osmotin mimics preventive effects of adiponectin on vascular inflammation and atherosclerosis","volume":"83","author":"Y Takahashi","year":"2018","journal-title":"Metabolism [Internet]"},{"key":"pone.0311214.ref016","article-title":"Osmotin Protects H9c2 Cells from Simulated Ischemia-Reperfusion Injury through AdipoR1\/PI3K\/AKT Signaling Pathway","author":"J Liu","year":"2017","journal-title":"Frontiers in Physiology"},{"issue":"1","key":"pone.0311214.ref017","doi-asserted-by":"crossref","DOI":"10.1038\/srep24493","article-title":"Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4\/NF\u03baB signaling pathway","volume":"6","author":"H Badshah","year":"2016","journal-title":"Scientific Reports"},{"issue":"2","key":"pone.0311214.ref018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jaci.2007.10.018","article-title":"inflammation: Consensus and controversy","volume":"121","author":"Fantuzzi G. Adiponectin","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"pone.0311214.ref019","doi-asserted-by":"crossref","first-page":"e16690","DOI":"10.1371\/journal.pone.0016690","article-title":"Structural and Functional Similarities between Osmotin from Nicotiana Tabacum Seeds and Human Adiponectin. Hofmann A, editor","volume":"6","author":"M Miele","year":"2011","journal-title":"PLoS ONE"},{"issue":"1","key":"pone.0311214.ref020","doi-asserted-by":"crossref","first-page":"e1026","DOI":"10.1038\/cddis.2013.538","article-title":"Novel osmotin attenuates glutamate-induced synaptic dysfunction and neurodegeneration via the JNK\/PI3K\/Akt pathway in postnatal rat brain","volume":"5","author":"SA Shah","year":"2014","journal-title":"Cell Death & Disease"},{"issue":"1","key":"pone.0311214.ref021","article-title":"Neuroprotective effects of osmotin in Parkinson\u2019s disease-associated pathology via the AdipoR1\/MAPK\/AMPK\/mTOR signaling pathways","volume":"30","author":"Jun Sung Park","year":"2023","journal-title":"Journal of Biomedical Science"},{"issue":"8","key":"pone.0311214.ref022","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/mt.2016.115","article-title":"Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells","volume":"24","author":"KC Kwon","year":"2016","journal-title":"Molecular Therapy"},{"issue":"4","key":"pone.0311214.ref023","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1073\/pnas.91.4.1371","article-title":"Chloride ions catalyze the formation of cis adducts in the binding of anti-benzo[a]pyrene diol epoxide to nucleic acids","volume":"91","author":"AR Wolfe","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America [Internet]"},{"issue":"20","key":"pone.0311214.ref024","doi-asserted-by":"crossref","first-page":"12361","DOI":"10.3390\/ijms232012361","article-title":"Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients","volume":"23","author":"M N\u00f6tzel","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"22","key":"pone.0311214.ref025","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"L Novakova","year":"2017","journal-title":"Neurology"},{"key":"pone.0311214.ref026","article-title":"Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients (S8.006)","author":"J Kuhle","year":"2018","journal-title":"Neurology [Internet]"},{"key":"pone.0311214.ref027","unstructured":"Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment | Cochrane Library [Internet]. Cochranelibrary.com. 2020 [cited 2024 Feb 7]. Available from: https:\/\/www.cochranelibrary.com\/web\/cochrane\/content?templateType=full&urlTitle=%2Fcentral%2Fdoi%2F10.1002%2Fcentral%2FCN-02147271&doi=10.1002%2Fcentral%2FCN-02147271&type=central&contentLanguage=."},{"issue":"1","key":"pone.0311214.ref028","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"S Meyer-Moock","year":"2014","journal-title":"BMC Neurology"},{"issue":"5","key":"pone.0311214.ref029","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122","author":"GR Cutter","year":"1999","journal-title":"Brain [Internet]"},{"issue":"5","key":"pone.0311214.ref030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5014\/ajot.57.5.570","article-title":"Adult Norms for a Commercially Available Nine Hole Peg Test for Finger Dexterity","volume":"57","author":"K Oxford Grice","year":"2003","journal-title":"American Journal of Occupational Therapy"},{"issue":"6","key":"pone.0311214.ref031","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)","volume":"18","author":"D Langdon","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"pone.0311214.ref032","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"RH Benedict","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"pone.0311214.ref033","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1177\/1352458509106615","article-title":"Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS","volume":"15","author":"L Strober","year":"2009","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"pone.0311214.ref034","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1191\/1352458506ms1289oa","article-title":"How to detect cognitive dysfunction at early stages of multiple sclerosis?","volume":"12","author":"MS Deloire","year":"2006","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"pone.0311214.ref035","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/brain\/122.7.1341","article-title":"Cognitive function in primary progressive and transitional progressive multiple sclerosis: A controlled study with MRI correlates","volume":"122","author":"SJ Camp","year":"1999","journal-title":"Brain"},{"issue":"12","key":"pone.0311214.ref036","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1177\/1352458510380089","article-title":"Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study","volume":"16","author":"MP Amato","year":"2010","journal-title":"Multiple Sclerosis Journal"},{"key":"pone.0311214.ref037","article-title":"Symbol Digit Modalities Test","author":"A. Smith","year":"1973"},{"issue":"4","key":"pone.0311214.ref038","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"ZS Nasreddine","year":"2005","journal-title":"Journal of the American Geriatrics Society [Internet]"},{"issue":"1","key":"pone.0311214.ref039","first-page":"2","article-title":"A study of cognitive impairments in Multiple Sclerosis: Occupational therapy perspective","volume":"44","author":"P. K. Abraham","year":"2012","journal-title":"The Indian Journal of Occupational Therapy"},{"issue":"2","key":"pone.0311214.ref040","article-title":"Screening for Cognitive Impairment in Multiple Sclerosis with MOCA Test","volume":"19","author":"A Selma","year":"2024","journal-title":"Turkish Journal of Neurology [Internet]"},{"issue":"3","key":"pone.0311214.ref041","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1017\/S0317167100014384","article-title":"Value of the MoCA Test as a Screening Instrument in Multiple Sclerosis","volume":"40","author":"E Dagenais","year":"2013","journal-title":"Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"},{"issue":"4","key":"pone.0311214.ref042","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad199","article-title":"Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study","volume":"5","author":"A Lerede","year":"2023","journal-title":"Brain communications"},{"issue":"1","key":"pone.0311214.ref043","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12)","volume":"60","author":"J.C. Hobart","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"pone.0311214.ref044","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale.","volume":"67","author":"AS Zigmond","year":"1983","journal-title":"Acta Psychiatrica Scandinavica [Internet]"},{"issue":"2","key":"pone.0311214.ref045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7224\/1537-2073.2013-013","article-title":"Validation of Mood Measures for People with Multiple Sclerosis","volume":"16","author":"TM Watson","year":"2014","journal-title":"International Journal of MS Care"},{"issue":"6","key":"pone.0311214.ref046","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Pyschometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"K Koyne","year":"2002","journal-title":"Qual Life Res"},{"issue":"24","key":"pone.0311214.ref047","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","article-title":"The APOSTEL recommendations for reporting quantitative optical coherence tomography studies","volume":"86","author":"A Cruz-Herranz","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"pone.0311214.ref048","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1352458514538110","article-title":"Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria","volume":"21","author":"S Schippling","year":"2014","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"pone.0311214.ref049","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/brain\/awaa361","article-title":"Retinal asymmetry in multiple sclerosis","volume":"144","author":"A Petzold","year":"2020","journal-title":"Brain"},{"issue":"9","key":"pone.0311214.ref050","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/jnnp.2005.086280","article-title":"Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study","volume":"77","author":"L Leocani","year":"2006","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry [Internet]"},{"issue":"10","key":"pone.0311214.ref051","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/1352458517707265","article-title":"A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS","volume":"23","author":"M Hardmeier","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"pone.0311214.ref052","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00415-005-0728-9","article-title":"Corticomotor organisation and motor function in multiple sclerosis","volume":"252","author":"G Thickbroom","year":"2005","journal-title":"Journal of Neurology"},{"key":"pone.0311214.ref053","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jns.2016.04.026","article-title":"Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy","volume":"365","author":"R Iodice","year":"2016","journal-title":"Journal of the Neurological Sciences [Internet]"},{"issue":"2","key":"pone.0311214.ref054","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458510386998","article-title":"Natalizumab restores evoked potential abnormalities in patients with relapsing\u2013remitting multiple sclerosis","volume":"17","author":"SG Meuth","year":"2010","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"pone.0311214.ref055","article-title":"Computational classifiers for predicting the short-term course of Multiple sclerosis","volume":"11","author":"B Bejarano","year":"2011","journal-title":"BMC Neurology [Internet]"},{"issue":"2","key":"pone.0311214.ref056","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clinph.2019.11.024","article-title":"Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis","volume":"131","author":"M Pisa","year":"2020","journal-title":"Clinical Neurophysiology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:27:10Z","timestamp":1740680830000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311214"}},"subtitle":[],"editor":[{"given":"Omid","family":"Beiki","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311214","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}